Sonay Incesoy Ozdemir

Sonay Incesoy Ozdemir

Auto-generated profile, based on publicly available information

Sonay Incesoy Ozdemir

Department of Pediatric Oncology Ankara University Faculty of Medicine Ankara Türkiye

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2020 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
SÖSonay İnCesoy Özdemi̇r
Sonay İnCesoy Özdemi̇r
NTNurdan Taçyildiz
Nurdan Taçyildiz
AVAli Varan
Ali Varan
RKRejin Kebudi
Rejin Kebudi
BZBülent Zülfi̇kAr
Bülent Zülfi̇kAr
MKMehmet Kantar
Mehmet Kantar
The main purpose of this study is to determine; the current status of long term follow up (LTFU) for childhood cancer survivors and the challenges of LTFU for pediatric cancer survivors at pediatric oncology institutions in Turkey. An e-mailed questionnaire has been sent to directors of 33 pediatric oncology centers registered in the Turkish Pediatric Oncology Group (TPOG).Twenty one of 33 active institutions of the TPOG participated in the study and returned their completed questionnaires. Only 1 of the 21 participating centers had a separate LTFU clinic. The remaining centers had provided LTFU care for chilhood cancer survivors at the pediatric oncology outpatient clinic. Seventeen (80.9%) centers reported difficulty transition from pediatric clinic to adult clinic, 14 centers (66.6%) reported insufficient care providers, 12 (57.1%) centers reported insufficient time and transportation problems. As neglected late effects; 16 (76.1%) centers reported psychosocial and getty job problems, 11 (52.3%) centers reported sexual and cognitive problems. None of the centers have their own LTFU guideline for their daily LTFU practice. This study is the first to gain an overview of the needs of pediatric oncology centers and the gaps in survivorship services in Turkey. The results from this study will help develope a national health care system and national guideline for pediatric cancer survivors.

25 June 2016 in The Turkish Journal of Pediatrics
Verified
Journal Article
Open access
SESuna Emir
Suna Emir
SÖSonay İnCesoy Özdemir
Sonay İnCesoy Özdemir
HDHacı Ahmet Demir
Hacı Ahmet Demir
DÖDerya Özyörük
Derya Özyörük
EKEsra Karakuş
Esra Karakuş
FÇFaik Çetindağ
Faik Çetindağ
In this study, clinical characteristics, treatment modalities and outcome of patients diagnosed with bladder/prostate rhabdomyosarcoma (BP RMS) were evaluated retrospectively. Files of 8 children diagnosed with BP RMS and treated between 2004-2014 were reviewed for clinical characteristics, treatment modalities and outcome. Seven males and one female were diagnosed with BP RMS between 2004-2014. Median age was 33.5 months (range, 2 to 176 months). At presentation the main clinical symptoms were hematuria in 5 patients, and constipation, oliguria and prolonged jaundice in 1 patient each. All patients were non-metastatic and only one had an embryonal histology. Primary resection before chemotherapy was performed on only one patient. Six patients were treated initially with VAC chemotherapy for 12 weeks, two patients were treated PIAV (ifosfamide, cisplatin, doxorubicin, vincristine). Local relapse or progressive disease occurred in 5 of 8 patients, and two of these patients underwent primary or secondary tumor resection without radiotherapy. Three patients developed a local relapse after combination of radiochemotherapy and tumor resection. Radical surgical treatment was performed in 3 patients with local relapse. Only one patient underwent partial cystectomy. Six of 8 patients were alive and under follow-up without disease at a median survival of 53 months (range, 13 to 78 months). BP RMS requires a multidisciplinary treatment approach. There is a general consensus that chemotherapy is the mainstay of treatment in BP RMS, but the method to be used for local control is controversial, and may vary from case to case in this heterogeneous disease.

8 December 2022 in Turkish Journal of Pediatric Emergency and Intensive Care Medicine
Verified
Journal Article
Closed access
SÖSonay İncesoy Özdemir
Sonay İncesoy Özdemir
HAHalise Akça
Halise Akça
AKAyşegül Neşe Çitak Kurt
Ayşegül Neşe Çitak Kurt

25 August 2017 in The Turkish Journal of Pediatrics
Verified
Journal Article
Open access
SISonay İnCesoy-Özdemir
Sonay İnCesoy-Özdemir
UEUlya Ertem
Ulya Ertem
GŞGürses Şahin
Gürses Şahin
CBCeyhun Bozkurt
Ceyhun Bozkurt
NYNazmiye Yüksek
Nazmiye Yüksek
AAAfra Alkan
Afra Alkan
Germ cell tumor (GCT) is a rare malignancy accounting for 2-3% of all pediatric tumors. The overall survival rate of children and adolescents with GCT is more than 80% after adopting combined therapy. The aim of this study is to review clinical presentation, management, and outcome in a single-center series with extracranial GCT. Clinical characteristics, pathologic presentations, and survival outcomes of 101 children with GCT, treated at our hospital from 1988 to 2011, were analyzed. Sixty-two of patients were female and 39 of them were male. Fifty-eight (57%) patients had gonadal tumor (24 testicular, 34 ovarian), 43 (43%) extragonadal. Histologically, teratomas were found most frequently (26 mature, 10 immature), followed by yolk sac tumors (n: 33), mixed malignant tumors (n: 13), embryonal carcinoma (n: 10), disgerminoma (n: 8) and seminoma (n: 1). Twenty-six patients were diagnosed as mature teratoma and we excluded them in the evaluation of staging and survival. Five-year overall and relaps-free survival were 80.3% (mean follow-up time: 215.8 months) and 73.4% (mean follow-up time: 176.2 months), respectively. Five-year survival rates were 93.2% and 90.2% in malign GCTs diagnosed after 1999.


25 June 2014 in The Turkish Journal of Pediatrics
Verified
Journal Article
Open access
SISonay İnCesoy-Özdemir
Sonay İnCesoy-Özdemir
NYNazmiye Yüksek
Nazmiye Yüksek
CBCeyhun Bozkurt
Ceyhun Bozkurt
GŞGürses Şahin
Gürses Şahin
LMLeyla Memiş
Leyla Memiş
UEUlya Ertem
Ulya Ertem
Primary ocular adnexal mucosa-associated lymphoid tissue (MALT) lymphomas (OAMLs) are mostly seen in the 5th-7th decades of life, with female predominance, and they occur rarely in children. Thus, knowledge about this cancer type is obtained from adult data in the literature, while the data regarding OAMLs in the pediatric population are limited to a few case reports. Herein, we report a 10-year-old boy with OAML who was treated successfully with radiotherapy, and we discuss this uncommon lymphoma in children.